https://www.taplowgroup.comInsight
https://www.taplowgroup.comTaplow
https://www.taplowgroup.comKnowledge
  • News
  • Cases
  • Downloads
The Taplow Group Strengthens its Footprint in Europe
23.01.2023

The Taplow Group Strengthens its Footprint in Europe

The Taplow Group S.A. is a leading global Executive Search, Human Capital, Board Advisory and Interim Executive company with 24 partner firms...
The Taplow Group 2021 Highlights
08.03.2022

The Taplow Group 2021 Highlights

Mark Firth, Chair – The Taplow Group S.A., reflecting on the results said. “We made excellent progress against our 2021 strategies,...
2022 Global Business Outlook Report
20.01.2022

2022 Global Business Outlook Report

The Taplow Group S.A. Our 20 global partner firms, combine to bring local, regional and global 2022 trends, economic and business news.
12345678910Last

 CEO FOR A SPORTS:

Situation: A Finnish, mainly nationally operating sports company needed new CEO as the old one was about to retire. As sports business is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contac Timo Toivanen, Finland

 

 

 CEO FOR LOGISTICS:

Situation: One of the largest globally operating Logistics companies was in a need of new CIO for Finland. As Logistics and Value Chain is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contac Timo Toivanen, Finland

White Papers
  • India – The new R&D hub for Automotive

    Taplow India have conducted an in-depth review of the Automotive sector in India, For further information contact Sangeeta Sabharwal, India

    Click Here
  • Maysam Rizvi reviews the Banking Tech Revolution.

    Capital is more expensive, costs are higher and prices have gone down… the technology revolution has become a necessity.

    Click Here
  • EVOLVING BUSINESS UNITS Market Access thus becoming “transversal”

    The pharmaceutical market, in regards to the price component covered by the NHS, has been, until today, characterised by the presence of drugs of high therapeutic value, such as cancer-drugs, rheumatologic drugs, anti-infection drugs and drugs for the treatment of chronic illnesses, the vast majority of which have either seen their patent expire recently or will see it expire in the next two years.

    Click Here
  • BUSINESS CYCLES

    Present Human Capital Opportunities and Challenges:

    Click Here